Dr. Andrew Louis Pecora is President of the Physicians Services Division and Chief Innovations Officer, Hackensack Meridian Health. He is the founder and served as President of Regional Cancer Care Associates. He is a Professor Medicine at UMDNJ- New Jersey Medical School and Professor of Oncology and Medicine at Georgetown University. Dr. Pecora has received the American Cancer Society Physicians in the Forefront Award (1997) and the Susan G. Komen Breast Cancer Foundation Award as a Hero in the fight against breast cancer (1998). He received the EBMT-ESMO Award at the International Conference on High dose chemotherapy in Breast and Ovarian Cancer in 2000. Dr. Pecora has been honored by the March of Dimes (2007), inducted into the Nutley Hall of Fame (2005) and given the distinguished citizen award by the Hackensack chamber of commerce for his contributions to research and patient care (2001). Dr Pecora received the Uber Elite Award in 2016. Dr. Pecora is also an entrepreneur having co-founded and served as Chairman and Chief Executive Officer of Progenitor Cell Therapy, L.L.C.; a company focused on facilitating the transfer of laboratory breakthrough to clinical application and practice in cell therapies. He also co-founded and served as Chairman of Amorcyte, Inc. a biotechnology company developing cell therapies for cardiovascular disease and founded COTA a healthcare software analytic company focused on enabling value based care delivery and serves as its Executive Chairman. He served on the board of Cancer Genetics and was chairman of the board of Tetralogics, Inc., a company developing small molecules to treat cancer.

Dr. Norden serves as Deputy Chief Health Officer with a leadership role in oncology and genomics. He is an oncologist and physician executive who joined Watson Health in 2016 after serving as Associate Chief Medical Officer at Dana-Farber Cancer Institute.  At Dana-Farber, Andrew led the Dana-Farber community network for more than 5 years. He was responsible for physician mentorship and supervision, quality improvement, patient safety, program development, clinical trials, implementation of a medical oncology clinical pathways program, and roll-out of the Epic EMR.

A talented physician and board-certified neuro-oncologist who has been on the Dana-Farber staff for 10 years, Andrew cares for patients with brain tumors and neurological complications of cancer. He has also developed many clinical trials for patients with glioma, meningioma, and seizures in brain tumor patients. He is the author of more than 50 peer-reviewed papers primarily involving therapy for high-grade gliomas and meningioma, in addition to a large number of review articles, book chapters, and presentations at national meetings. He is an active member of the American Society of Clinical Oncology, the Society for Neuro-Oncology, and the American Academy of Neurology, and he is an Associate Editor of JCO-Clinical Cancer Informatics.

Dr. Norden attended medical school at Yale School of Medicine before coming to Boston for residency training at Massachusetts General and Brigham and Women’s Hospitals. After serving as Chief Resident, he completed a neuro-oncology fellowship at Dana-Farber. Dr. Norden is based in Cambridge, Massachusetts.

Jennifer L. Wong is the Chief of Strategic Alliances for CancerLinQ LLC, a big data and health technology venture of the American Society of Clinical Oncology (ASCO). As a business executive, spokesperson and global brand ambassador for CancerLinQ, Jennifer leads strategy and alliances by creating novel public, private and not-for-profit partnerships with institutions and influencers. With experience across the healthcare, big data and technology sectors, she is a change agent that has brought together the power of partnership and innovation to drive thought leadership, build coalitions across ecosystems, launch key engagements and accelerate the development of novel data-driven solutions and ventures to create measurable impact.

Prior to joining CancerLinQ, Jennifer served as the Director of Strategic Innovation and Clinical Ventures at the American College of Cardiology (ACC). As Managing Director of the Diabetes Collaborative Registry®, she was instrumental in the launch of the first global, multispecialty, clinical, big data diabetes initiative with a network of leading organizations, and led growth and development strategy for the PINNACLE (Practice Innovation and Clinical Excellence) Registry®, the largest ambulatory cardiovascular quality improvement registry in the United States. Jennifer also worked in medical education at the Association of American Medical Colleges, co-founded an educational technology startup, and led national-scale admissions recruitment strategies to advance talented young women in their pursuit of science, technology, engineering and mathematics (STEM) fields.

Jennifer graduated from the Massachusetts Institute of Technology (MIT) with a degree in Biology and concentrations in Spanish and Brain and Cognitive Sciences. She is a graduate of the Singularity University Executive Program for Exponential Technologies and completed graduate studies in Digital Media Marketing Strategy at New York University (NYU). She earned Pi Alpha Alpha highest honors as a Master of Public Policy in Innovation and Strategic Management from The George Washington University (GWU) in Washington, D.C.

Alex K. Shalek is currently the HLF von Helmholtz Career Development Assistant Professor of Health Sciences and Technology at MIT, as well as a Core Member of the Institute for Medical Engineering and Science (IMES) and an Assistant Professor of Chemistry. He is also an Associate Member of the Ragon and Broad Institutes, and an Assistant in Immunology at MGH. His research is directed towards the development and application of new technologies that facilitate understanding of how cells collectively perform systems-level functions in healthy and diseased states. Dr. Shalek received his bachelor's degree summa cum laude from Columbia University and his Ph.D. from Harvard University in chemical physics under the guidance of Hongkun Park, and performed postdoctoral training under Hongkun Park and Aviv Regev (Broad/MIT). To date, his interdisciplinary research has focused on realizing and utilizing nanoscale manipulation and measurement technologies to examine how small components (molecules, cells) drive systems of vast complexity (cellular responses, population behaviors).

Melissa joined Pfizer in 2004 and has spent more than 8 years in the oncology business.  She is currently a leader in the Global Oncology Strategy and Innovation Group. 

In this role, Melissa is responsible for external portfolio collaborations for both preclinical and clinical assets.  She is also leading a number of patient engagement projects that utilize novel technologies and engage regulatory authorities around new approaches to data generation and collection.  In addition, she is accountable for shaping and executing Pfizer Oncology’s real world data strategy.  Her work is focused on enabling the generation of real world evidence across the development continuum from discovery through development, access and commercialization in order to decrease patient burden, while delivering cancer medicines to patients faster.

Prior to her current role, Melissa held positions leading the U.S. hematology sales and marketing teams, as well as global and commercial operations.  She has experience in business development and previously spent a number of years practicing law at Pfizer and other corporate law firms in New York City.  She attended Harvard Law School and Harvard College.